Clinical Trial Update: The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the effect of phosphate lowering with sucroferric oxyhydroxide (PA21) on serum calcification propensity in end-stage renal disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endstage Renal Disease

Drugs mentioned

• Sucroferric oxyhydroxide (PA21) (sucroferric oxyhydroxide)

Snippet

Sponsor: Prim. Priv. Doz. Dr. Daniel Cejka | Conditions: Endstage Renal Disease | Phase 2 | Status: COMPLETED